Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microbial membrane proteins and lipid bilayers are fundamental components of the cell envelope in bacteria, fungi, and other microorganisms, providing a selective barrier and a platform for essential biological processes. These structures are involved in maintaining ion gradients, facilitating nutrient uptake through transporters, and housing the machinery for ATP synthesis and cell wall biogenesis (Strahl & Hamoen, 2010; Epand et al., 2016). In drug development, the microbial membrane is a high-value target because its composition—such as the high content of anionic phospholipids in bacteria or ergosterol in fungi—differs significantly from the cholesterol-rich membranes of mammalian cells (Zhang & Rock, 2008). Antimicrobial agents like daptomycin and polymyxins exploit these differences to bind, insert into, and disrupt the membrane, often leading to rapid depolarization and cell death (Silverman et al., 2003; Landman et al., 2008). While highly effective against multi-drug resistant pathogens, targeting these structures poses challenges due to potential off-target effects on host membranes, which can manifest as nephrotoxicity or neurotoxicity (Falagas & Kasiakou, 2006). Consequently, research continues to focus on enhancing the selectivity of membrane-active agents to expand their therapeutic index in treating severe infections (Hurdle et al., 2011).
Antimicrobial agents targeting this system primarily function by disrupting the structural integrity of the lipid bilayer or inhibiting the function of essential membrane-embedded proteins. Mechanisms include the formation of transmembrane pores, induction of rapid membrane depolarization, and the sequestration of vital lipids like ergosterol or lipid II, which leads to the leakage of essential ions and metabolites, ultimately resulting in cell lysis or metabolic arrest (Silverman et al., 2003; Landman et al., 2008; Hurdle et al., 2011).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbial membrane proteins and lipid bilayers.